As of June 30, 2023, the company had cash, cash equivalents and marketable securities of $151.0 million, which is expected to fund operations into 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACRV:
- Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
- Acrivon appoints Levy as SVP, head, investor relations and corporate affairs
- Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors